Compare UiPath Inc (PATH) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Teladoc Health Inc — how do they compare? UiPath Inc trades at $10.64 (market cap $6.24B), while Teladoc Health Inc trades at $8.88 (market cap $1.75B). The key difference: UiPath Inc is far larger — about 3.6× Teladoc Health Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| PATH | TDOC | |
|---|---|---|
Market Cap | $6.24B | $1.75B |
Sector | Technology | Health |
52-Week High | $19.29 | $9.72 |
52-Week Low | $9.38 | $4.47 |
Enterprise Value | $5.01B | $2.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $12.04, down 0.91% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while narrowing net losses signal a path toward sustained profitability. Recent news highlights strong annual recurring revenue growth to $1.9B and strategic AI automation developments through its Maestro platform.
The investment outlook is cautiously optimistic, supported by analyst consensus and improving margins, but risks include competitive pressures in AI automation and volatility in software spending. The stock presents a potential opportunity if execution on profitability continues, though near-term earnings misses warrant monitoring.
TDOC trades at $9.71, up 2.97% with a bullish technical signal. The stock shows improving fundamentals with revenue stabilizing around $2.5B and narrowing losses. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Positive sentiment is driven by partnerships like Walmart Better Care and cost-cutting initiatives, though net margins remain negative.
The outlook suggests cautious optimism as operational improvements may drive recovery, but persistent losses and high debt pose risks. Analyst consensus is mixed with 36% buy ratings and a $9.50 price target, indicating limited upside. Investors should weigh cost-control progress against competitive pressures in telehealth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
